Biomarkers for Systemic Therapy in Metastatic Breast Cancer
Key Points
Key Points
Testing for ESR1, PIK3CA, AKT1 and inactivation of PTEN somatic variants and germline BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) pathogenic variants (mutations) to guide therapy.
Testing tumors for homologous recombination deficiency, expression of programmed cell death ligand-1 (PD-L1), deficient mismatch repair microsatellite instability (dMMR/MSI), tumor mutational burden (TMB), neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and trophoblast cell-surface antigen 2 (TROP2) expression to determine eligibility for selected treatments.
The use of cell-free, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for monitoring treatment response.
Treatment
...atment
...from 2024 Rapid Recommendation Update...
...ecommendation 1.1The Expert Panel recommends...
...endation 1.2There are no comparative efficacy...
...tment Options According to Prior Endocrine Therap...
...commendations from 2023 Rapid Recommendation Up...
...aid in treatment selection, the Expert Panel recom...
...previously treated with ET and a CDK4...
...from 2022 Focused Guideline Update...
...dation 1.1Patients with locally recurrent...
...mmendation 3.1Patients with metastatic HER2...
...on 3.2There is insufficient evidence t...
...mmendation 4.1There are insufficien...
...ecommendation 5.1Patients with locally...
...dation 6.1Patients with metastatic cancer who a...
...commendation 7.1Patients with metastati...
...mendation 8.1Clinicians may test for NT...
...endation 9.1There are insufficient d...
...10.1There are insufficient data to reco...
...n 11.1There are insufficient data to recomme...
...ndations Unchanged From 2015 Guid...
...presentation of metastasis from breast c...
...mendation for Tissue Bioma...
...ents who are already receiving systemic thera...
...dations for Circulating Tumor Marker...
In patients already receiving systemic therapy...
...bryonic antigen (CEA), cancer antigen (CA) 15-3, a...
...ance Guide to ASCO Biomarker Testing in...
...s Recommended by the ASCO Expert PanelHa...
...arker Tests Not Recommended by the...
...ble 2. At-A-Glance Guide to ASCO Bio...
...ance Guide to ASCO Biomarker Testing in...
...believes that cancer clinical trials are vital to...